These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 21325869

  • 1. Relationship between biochemical markers and radial cortical bone changes in hemodialysis patients.
    Fujimori A, Okada S, Sakai M, Tome K, Fukagawa M.
    Nephron Clin Pract; 2011; 118(4):c375-9. PubMed ID: 21325869
    [Abstract] [Full Text] [Related]

  • 2. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M.
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
    [Abstract] [Full Text] [Related]

  • 3. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
    O'Flaherty D, Sankaralingam A, Scully P, Manghat P, Goldsmith D, Hampson G.
    Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
    [Abstract] [Full Text] [Related]

  • 4. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
    Małyszko J, Małyszko JS, Pawlak K, Wołczyński S, Myśliwiec M.
    Adv Med Sci; 2006 Oct; 51():69-72. PubMed ID: 17357281
    [Abstract] [Full Text] [Related]

  • 5. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
    Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Heikkinen JE, Suominen H, Cheng S, Väänänen HK.
    Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
    [Abstract] [Full Text] [Related]

  • 6. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
    Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y.
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
    [Abstract] [Full Text] [Related]

  • 7. Association between indoxyl sulfate and skeletal resistance in hemodialysis patients.
    Goto S, Fujii H, Hamada Y, Yoshiya K, Fukagawa M.
    Ther Apher Dial; 2010 Aug 01; 14(4):417-23. PubMed ID: 20649763
    [Abstract] [Full Text] [Related]

  • 8. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.
    Malluche HH, Davenport DL, Cantor T, Monier-Faugere MC.
    Clin J Am Soc Nephrol; 2014 Jul 01; 9(7):1254-62. PubMed ID: 24948144
    [Abstract] [Full Text] [Related]

  • 9. Bone responsiveness to parathyroid hormone is negatively associated with parathyroid hormone-lowering drug use in patients undergoing hemodialysis: a cross-sectional study.
    Tominaga N, Yonaha T, Yamanouchi M, Sumi H, Taki Y, Shibagaki Y, Shiizaki K, Yano S.
    BMC Nephrol; 2021 Aug 09; 22(1):275. PubMed ID: 34372813
    [Abstract] [Full Text] [Related]

  • 10. Usefulness of bone resorption markers in hemodialysis patients.
    Hamano T, Tomida K, Mikami S, Matsui I, Fujii N, Imai E, Rakugi H, Isaka Y.
    Bone; 2009 Jul 09; 45 Suppl 1():S19-25. PubMed ID: 19332165
    [Abstract] [Full Text] [Related]

  • 11. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
    Yamada S, Tsuruya K, Yoshida H, Taniguchi M, Haruyama N, Tanaka S, Eriguchi M, Nakano T, Kitazono T.
    Clin Endocrinol (Oxf); 2013 Jun 09; 78(6):844-51. PubMed ID: 23078546
    [Abstract] [Full Text] [Related]

  • 12. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease.
    Janckila AJ, Lederer ED, Price BA, Yam LT.
    Clin Nephrol; 2009 Apr 09; 71(4):387-96. PubMed ID: 19356371
    [Abstract] [Full Text] [Related]

  • 13. Mineral bone disorder and osteoporosis in hemodialysis patients.
    Slouma M, Sahli H, Bahlous A, Laadhar L, Smaoui W, Rekik S, Gharsallah I, Sallami M, Moussa FB, Elleuch M, Cheour E.
    Adv Rheumatol; 2020 Feb 26; 60(1):15. PubMed ID: 32102689
    [Abstract] [Full Text] [Related]

  • 14. Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism.
    Lu KC, Ma WY, Yu JC, Wu CC, Chu P.
    Clin Endocrinol (Oxf); 2012 May 26; 76(5):634-42. PubMed ID: 22007930
    [Abstract] [Full Text] [Related]

  • 15. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
    Nowak Z, Konieczna M, Wańkowicz Z.
    Pol Merkur Lekarski; 2004 Aug 26; 17(98):138-41. PubMed ID: 15603322
    [Abstract] [Full Text] [Related]

  • 16. Relevance of parathyroid hormone (PTH), vitamin 25(OH)D3, calcitonin (CT), bone metabolic markers, and bone mass density (BMD) in 860 female cases.
    Zhang M, Li Y, Ma Q, Mao W, Gao Y, Liu Y, Liang B.
    Clin Exp Obstet Gynecol; 2015 Aug 26; 42(2):129-32. PubMed ID: 26054103
    [Abstract] [Full Text] [Related]

  • 17. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
    Okuno S, Ishimura E, Tsuboniwa N, Norimine K, Yamakawa K, Yamakawa T, Shoji S, Mori K, Nishizawa Y, Inaba M.
    Osteoporos Int; 2013 Feb 26; 24(2):605-12. PubMed ID: 22581293
    [Abstract] [Full Text] [Related]

  • 18. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.
    Nagata Y, Inaba M, Imanishi Y, Okazaki H, Yamada S, Mori K, Shoji S, Koyama H, Okuno S.
    Osteoporos Int; 2015 Mar 26; 26(3):1053-61. PubMed ID: 25403902
    [Abstract] [Full Text] [Related]

  • 19. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
    Lu KC, Tseng CF, Wu CC, Yeung LK, Chen JS, Chao TY, Janckila AJ, Yam LT, Chu P.
    Blood Purif; 2006 Mar 26; 24(5-6):423-30. PubMed ID: 16888370
    [Abstract] [Full Text] [Related]

  • 20. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y, Kasai H, Ose A, Serada M, Ishiguro M, Shiraki M, Tanigawara Y.
    Osteoporos Int; 2018 May 26; 29(5):1155-1163. PubMed ID: 29423715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.